Molecular Matrix (MMI) signed a Memorandum of Understanding with Philosys Healthcare to expand availability of next-generation bone graft substitute technology in Asia.
MMI has developed a scaffold for bone tissue regeneration based on synthetically hyper-crosslinked carbohydrate polymer (HCCP) chains that are non-immunogenic, biocompatible, biodegradable and highly versatile for tissue engineering. HCCP is the platform for MMI’s Osteo-P™ Bone Graft Substitute.
Philosys, a biomedical distribution and manufacturing company, is based in Seongnam, South Korea. Osteo-P BGS is expected to open up its access to the orthopedic markets in Asia, as well as the dental and veterinary segments. Philosys also plans to pursue an equity investment in MMI.
Molecular Matrix (MMI) signed a Memorandum of Understanding with Philosys Healthcare to expand availability of next-generation bone graft substitute technology in Asia.
MMI has developed a scaffold for bone tissue regeneration based on synthetically hyper-crosslinked carbohydrate polymer (HCCP) chains that are non-immunogenic, biocompatible,...
Molecular Matrix (MMI) signed a Memorandum of Understanding with Philosys Healthcare to expand availability of next-generation bone graft substitute technology in Asia.
MMI has developed a scaffold for bone tissue regeneration based on synthetically hyper-crosslinked carbohydrate polymer (HCCP) chains that are non-immunogenic, biocompatible, biodegradable and highly versatile for tissue engineering. HCCP is the platform for MMI’s Osteo-P™ Bone Graft Substitute.
Philosys, a biomedical distribution and manufacturing company, is based in Seongnam, South Korea. Osteo-P BGS is expected to open up its access to the orthopedic markets in Asia, as well as the dental and veterinary segments. Philosys also plans to pursue an equity investment in MMI.
Copy to clipboard 
